To explore Ad5-Ki67/IL-15’s contribution to augmenting anti-glioma efficacy, we constructed the Ad5-Ki67 using the Ki67 promoter gene instead of the type 5 adenovirus endogenous promoter of the E1A gene, as well as CMV promoter-regulated replication defects adenovirus Ad5-GFP (1 × 1012 vp/ml). The gene discussed is DHTKD1; the disease is central nervous system cancer.